Learn how zangontinib affects statins and liver risk, when to switch to pravastatin, and how to monitor labs remotely for hepatitis B safety.
Evan Wu, MD, PhD
Evan Wu, MD, PhD, is a board-certified hematologist-oncologist with expertise in translational research and development of clinical trials with a special interest in lung cancer and head and neck cancer at The Oncology Institute of Hope & Innovation.
Articles by Evan Wu, MD, PhD
Learn how zangontinib affects atorvastatin, raises liver-risk, and why frequent LFTs plus entecavir may prevent hepatitis B reactivation.
NCCN guidance highlights how HER2-mutant lung cancer may still benefit from chemo‑immunotherapy, as PD‑L1 and response patterns differ from EGFR/ALK/RET/ROS1.
Limited lung cancer tissue? Pair liquid biopsy with NGS to spot actionable mutations fast and choose targeted therapy without delaying care.
Explore first-line therapy for HER2-mutated advanced NSCLC in an older patient, covering biomarker testing, liquid biopsy timing, and tailored HER2-targeted options.